Invitation - Presentation of Sobi's Q2 2018 Results

STOCKHOLM, July 2, 2018 /PRNewswire/ -- On 18 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2018.

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00 CET. The event will be hosted by Sobi's CEO and President, Guido Oelkers, and the presentation will be held in English.

The presentation can be followed live, or afterwards on Slides used in the presentation will be made available on Sobi's website prior to the telephone conference.

To participate in the telephone conference, please call:
SE: +46-8-566-42-697
UK: +44-203-008-98-09
US: +1-855-753-22-36

Click here to go to the live webcast.

After the live event the webcast will be available on-demand via the same URL.

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our vision is to be recognised as a global leader in providing access to innovative treatments that transform lives for individuals with rare diseases. The product portfolio is primarily focused on treatments in Haemophilia and Specialty Care. Partnering in the development and commercialisation of products in specialty care is a key element of our strategy. Sobi has pioneered in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2017, Sobi had total revenues of SEK 6.5 billion and approximately 850 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at

For more information please contact:

Media relations
Linda Holmström,
Senior Communications Manager

Investor relations
Jörgen Winroth,
Vice President,
Head of Investor Relations


This information was brought to you by Cision,c2565991

The following files are available for download: PDF

View original content:

SOURCE Swedish Orphan Biovitrum AB

Company Codes: Berlin:B6E, OTC-PINK:SWTUY, Bloomberg:SOBI@SS, ISIN:SE0000872095, OTC-PINK:BIOVF, RICS:SOBI.ST, Stockholm:SOBI, Dusseldorf:B6E, Frankfurt:B6E, Munich:B6E

Back to news